Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVJWPR)

Drug Name
TOK-001 Drug Info
Synonyms
Galeterone; 851983-85-2; Galaterone; VN/124-1; UNII-WA33E149SW; TOK 001; VN/124; WA33E149SW; (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Galeterone [USAN:INN]; Galeterone (USAN); TOK-001(Galeterone); SCHEMBL939234; GTPL8638; 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol; CHEMBL2105738; Galeterone, &gt
Cross-matching ID
PubChem CID
11188409
ChEBI ID
CHEMBL2105738
CAS Number
CAS 851983-85-2
TTD Drug ID
D0U0BU

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mucin type O-glycan biosynthesis 1.98 0.00e+0 20/36 (55.56%) B4GALT5;GALNT10;GALNT3;...
Glyoxylate and dicarboxylate metabolism -1.62 4.74e-2 23/30 (76.67%) PCCB;MDH2;MMUT;...
Tyrosine metabolism -1.63 4.86e-2 30/36 (83.33%) HGD;MAOB;ALDH3B1;...
Aminoacyl-tRNA biosynthesis -1.64 4.47e-2 15/66 (22.73%) GATB;GATC;QRSL1;...
Pyruvate metabolism -1.64 4.73e-2 41/47 (87.23%) FH;GLO1;PKLR;...
Amphetamine addiction -1.66 4.27e-2 57/69 (82.61%) CAMK2A;HDAC2;GRIA2;...
Tryptophan metabolism -1.69 3.35e-2 35/42 (83.33%) DLD;ACAT1;ALDH7A1;...
Propanoate metabolism -1.69 3.50e-2 30/34 (88.24%) ACADS;ECHDC1;PCCB;...
Pentose and glucuronate interconversions -1.69 3.85e-2 17/34 (50%) UGP2;AKR1A1;UGT2A3;...
Butanoate metabolism -1.70 3.98e-2 23/28 (82.14%) ACAT1;EHHADH;BDH2;...
Histidine metabolism -1.70 4.25e-2 16/22 (72.73%) ALDH7A1;MAOB;ALDH3B1;...
Primary bile acid biosynthesis -1.71 4.86e-2 15/17 (88.24%) CYP46A1;SLC27A5;ACOX2;...
Ascorbate and aldarate metabolism -1.73 3.88e-2 15/30 (50%) AKR1A1;UGT2A3;ALDH2;...
Metabolism of xenobiotics by cytochrome P450 -1.80 2.33e-2 49/77 (63.64%) CYP2D6;MGST2;AKR7A2;...
Parkinson disease -1.84 1.79e-2 176/249 (70.68%) TUBA1A;ATP5PB;MAPT;...
Peroxisome -1.86 2.09e-2 72/82 (87.8%) SLC27A2;ACOX3;AGXT;...
Valine, leucine and isoleucine degradation -1.86 2.68e-2 42/48 (87.5%) PCCB;MMUT;DLD;...
Oxidative phosphorylation -2.03 0.00e+0 93/133 (69.92%) NDUFAB1;ATP6V1A;ATP5F1D;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H